

FEEL THE DIFFERENCE with MERIVA® Bioavailable Curcumin

Your premium source of turmeric



TOP TEN REASONS

- 1 Phytosome Bioavailable Technology:**
Studies have shown Meriva® to improve bioavailability of curcuminoids by 29-fold over an unformulated curcuminoid mixture.^{1,2}
- 2 Faster Absorption:**
Curcuminoids absorb about two times faster from Meriva®.^{1,2}
- 3 Longer Lasting:**
Stays in the bloodstream longer; Improved plasma C_{max} and AUC of curcuminoids near 30-fold over the standard turmeric extracts.^{1,2}
- 4 Clinical Studies:**
Meriva® is supported by 35 published clinical studies for 15 different health conditions confirming its safety and efficacy, more than any other turmeric-based ingredient.
- 5 Healthy Inflammation Response:**
Clinical studies revealed improvement for a healthy inflammation response in numerous conditions.³⁻⁸
- 6 Joint Health Improvement:**
Clinical studies conducted with Meriva® on patients demonstrated significant improvements for joint health related to flexibility, mobility and overall quality of life.^{3,4}
- 7 Eye Health:**
A long-term study has shown Meriva® to support ocular health^{5,6}, confirms the inflammatory response markers are supported, and the safety of Meriva®.
- 8 Great for Athletes:**
Reduced Muscle Soreness from oxidative stress and inflammation associated from continuous exercise, statistically significant reduction of IL-8 vs placebo and IL-6, reduction of MRI evidence of muscle stress.^{7,8}
- 9 Decreased C-Reactive Protein Levels:**
CRP, the measure of general levels of inflammation in your body, decreased 16-fold in individuals with elevated CRP.^{3,4}
- 10 Whole Body Wellness:**
Meriva® is a whole-body support ingredient and has been successfully studied for muscle, joint, bone, liver, kidney, prostate, cardiovascular and gastrointestinal health.

References

- ¹ Cuomo J. et al., *J Nat Prod.* 2011, 74,4, 664-669.
- ² Marczylo T.H. et al., *Cancer Chemother. Pharmacol.* 2007, 60 (2), 171-7.
- ³ Belcaro G. et al., *Panminerva Medica* 2010, 52 (2 Suppl 1), 55-62.
- ⁴ Belcaro G. et al., *Altern Med Rev.* 2010, 15(4):337-44.
- ⁵ Allegri P. et al., *Clinical Ophthalmology.* 2010, 4, 1201-1206.
- ⁶ Steigerwalt R. et al., *Panminerva Med.* 2012 54 (Suppl. 1 to No. 4): 11.
- ⁷ Drobnic F. et al., *J Int Soc Sports Nutr.* 2014 Jun; 18:11:31.
- ⁸ Sciberras JN. et al., *J Int Soc Sports Nutr.* 2015 Jan 21:12(1):5.